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1.1 Heart failure 
Heart failure (HF) is present when the heart is incapable of providing necessary metabolic 
needs of body tissues (Tanai and Frantz 2015). The prevalence of HF is higher in the older 
population. About 6-10% of people aged > 65 years are considered to be affected by HF. 
The relative incidence of HF is lower in women. However, at least 50% of the HF cases are 
female due to the better life expectancy (Mann et al. 2018). Management of HF patients has 
a high financial burden for the healthcare system; for example, current US costs for HF are 
estimated at $30 billion per year (Heidenreich et al. 2013, Mazurek and Jessup 2017). 
Coronary artery disease (CAD) is a major HF cause in industrialized countries. Hypertension 
is well known to be responsible for 75% of HF cases, including most patients with CAD 
(Mann et al. 2018). Likely, diabetes mellitus intensifies the development of HF. The risk of 
HF multiplies when all CAD, hypertension, and diabetes co-exist (Mann et al. 2018). About 
20-30% of cases of HF with reduced ejection fraction (HFrEF) remain idiopathic (Mann et 
al. 2018). These patients are referred to as non-ischemic or idiopathic cardiomyopathy. Other 
less common causes of HF include prior viral infection and toxin exposure. High cardiac 
output (e.g., arteriovenous fistula, anemia) could also lead to HF without any previously 
known structural heart disease. However, structural heart disease can develop into overt HF 
(Mann et al. 2018).  
HF can be described as acute or chronic according to disease progress or onset. 
Compensated HF is present when a measurable dysfunction of cardiac pump function co-
exists with predictable symptoms of HF, which include shortness of breath on exertion. 
Decompensated HF is present when these predictable symptoms of HF change and the 
situation worsens acutely (Schneider et al. 2018). 
Left-sided HF is mostly a result of ventricular myocardial disorders such as cardiomyopathy 
or myocardial infarction. Likely, HF could emerge secondarily as a result of valvular heart 
disease or hypertension. Primary known causes of right HF are increased pulmonary vascular 
resistance (e.g., lung disease with cor pulmonale), right heart valvular disease, and shunt 
disease with volume overload. A decompensated left HF can secondarily develop into right 
HF or global HF as well.   
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HFrEF, previously known as systolic HF, is defined by marked dysfunction of cardiac 
contraction. However, HF with preserved ejection fraction (HFpEF), otherwise known as 
diastolic HF, results from dysfunctional cardiac filling.  According to echocardiographic 
characteristics, HF patients with decreased ejection fraction (EF < 40%) and symptoms of 
HF are categorized as HFrEF (ESC 2016). The definition of HFpEF is a little bit more 
complicated. Symptomatic HF patients with EF ≥ 50% are called HFpEF when they show 
elevated natriuretic peptides and at least one of the following additional criteria: relevant 
structural heart disease or evidence of diastolic dysfunction (ESC 2016, Schneider et al. 
2018). The New York Heart Association classification (NYHA) categorizes HF patients 
based on their exercise tolerance (Table 1, Mann et al. 2018). The NYHA classification is 
essential to validate particular therapy indications and inclusion in clinical trials (Januzzi et al. 
2018). 




I No limitation in physical activity. Ordinary physical activity does not cause symptoms of 
HF. 
II Slight limitation in physical activity. Comfortable at rest, but ordinary physical activity 
results in symptoms of HF. 
III Marked limitation in physical activity. Comfortable at rest, but less than ordinary activity 
causes symptoms of HF. 
VI Unable to perform any physical activity without symptoms of HF or symptoms of HF at 
rest. 
 
Worsening dyspnea is a major symptom of HF, and it is commonly the result of an increase 
in cardiac filling pressure or reduced cardiac output (Januzzi et al. 2018). HF patients may try 
to sleep in an upright position to decrease the dyspnea (orthopnea). Paroxysmal nocturnal 
dyspnea and Cheyne-Stokes respiration are frequently overlooked symptoms (Januzzi et al. 
2018). Fatigue is a consequence of a reduction in cardiac output or abnormal metabolic 
responses of the skeletal muscle to exercise (Januzzi et al. 2018). Unintended weight loss, 
often leading to cachexia, is well known to have a prognostic value among HF patients 




Jugular venous pressure (JVP) is a reliable tool to evaluate volume retention. An elevated 
JVP has reasonable sensitivity (70%) and specificity (79%) for increased left-sided filling 
pressure (Januzzi et al. 2018). Pleural effusions commonly emerge bilaterally. However,  
unilateral pleural effusion resulting from HF usually presents on the right side (Januzzi et al. 
2018). Lower extremity edema may result from volume retention or a side effect of 
pharmacologic therapy (e.g., calcium channel blockers, Januzzi et al. 2018).  
HF is essentially a clinical diagnosis. However, several diagnostic tools are frequently used to 
ascertain the diagnosis. Two-dimensional echocardiography provides a semi-quantitative 
assessment of left ventricular size, function, or possible structural disorders. In this regard, 
EF is a crucial parameter to assess cardiac function. EF ≥ 50% usually reflects an adequate 
systolic function (Mann et al. 2018). Prominent reduced EF < 40% is assumed to be a sign 
of significantly impaired cardiac pump function (Mann et al. 2018).  
Cardiopulmonary exercise testing (CPET) is a routine method for assessment of exercise 
capacity. Besides, CPET is applied to evaluate the prognosis or response to therapy (Mann 
et al. 2018). Furthermore, CPET could also serve as an initial diagnostic tool in the early 
stages of heart failure (Malhotra et al. 2016).  A peak oxygen uptake (peakVO2) < 14 
mL/kg/min has been shown to correlate with poor prognosis (Anker et al. 1997, Mann et 
al. 2018). Specific cut-offs for peakVO2 have been defined to assess eligibility for heart 
transplantation (Ramos-Barbón et al. 1999). 
1.2 Co-morbidities of  heart failure 
Most discussed co-morbidities of HF such as chronic kidney disease (CKD, Schefold et al. 
2015), diabetes mellitus (Kim et al. 2010), or chronic obstructive pulmonary disease (COPD, 
Lainscak et al. 2015) affect about 30-50% of HF patients (von Haehling 2017a). Other co-
morbidities include hypertension, obesity, anemia, and atrial fibrillation (von Haehling 
2017a). Sleep apnea is discussed as an independent risk factor of death in patients with HF 
(Javaheri et al. 2011). Muscle wasting, also known as sarcopenia, is primarily known as a 
geriatric disorder. However, similar loss in muscle mass and strength is observed among HF 
patients (von Haehling 2017a). A recent consensus suggests differentiating primary 
sarcopenia (i.e., a result of aging) from secondary sarcopenia. The secondary sarcopenia is 
discussed to be a consequence of advanced underlying disorders such as HF (Bauer et al. 
2019). Iron deficiency has recently received tremendous attention (von Haehling 2017a). In 
the framework of CONFIRM-HF, Ponikowski et al. in 2015 showed a significant 
improvement in functional performance and quality of life (QOL) of HF patients with iron-
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deficiency after one year of therapy with ferric carboxymaltose (FCM, Ponikowski et al. 
2015). 
 
Figure 1. The estimated prevalence of some important co-morbidities in patients with HF 
(von Haehling 2017a). Usage with kind permission of the publisher (John Wiley and Sons). 
 
1.3 Wasting in heart failure 
The term wasting describes the loss of tissue independent of its type because adipose tissue, 
muscle, and bone can likewise be affected. The term "sarcopenia" from Greek "sarx" (flesh) 
and "penia" (loss), meaning poverty of flesh, was initially suggested in 1989 by Rosenberg to 
describe muscle changes that occur during healthy aging (von Haehling et al. 2017b, 
Rosenberg 2011). The annual loss of 1-2% of muscle mass has been discussed during the 
normal aging process (Abellan van Kan G 2009, von Haehling et al. 2017b). The term 
cachexia means "bad condition" (derived from the Greek "kako ́s" for bad and "hexis" for 
condition, von Haehling et al. 2017b). Many chronic diseases have been shown to result in 
significant weight loss (von Haehling et al. 2017b). A state of involuntary weight loss that 
cannot be reversed by changes in nutritional intake is described as cachexia (von Haehling et 
al. 2017b). Cachexia occurring in the process of HF is called cardiac cachexia (von Haehling 
et al. 2017b). Anker et al. (2003) showed weight loss ≥ 6% as the strongest predictor of death 
among HF patients. This cut-off showed the most prognostic value between other suggested 
percentages to define cardiac cachexia (Anker et al. 2003). 
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1.3.1 Pathophysiology of muscle wasting in heart failure  
Reduced cardiac output and systemic congestion in chronic HF lead to reduced food intake 
and exercise capacity (Yin et al. 2019). Furthermore, it initiates the release of inflammatory 
factors, increases sympathetic excitability and secretion of muscle-related hormones (Yin et 
al. 2019). These parameters' interaction leads to a decline in skeletal muscle growth factors 
and an increase in oxidative damage. The oxidative stress induces the ubiquitin-proteasome 
system (UPS) activity and increases autophagy and apoptosis (Yin et al. 2019).  
Skeletal muscle includes different fiber types. Slow-twitch type I fibers specialized for 
continuously extended muscle contractions use mainly aerobic metabolism. Fast-twitch type 
II fibers are responsible for quick contraction, which in contrast to type I fibers, usually uses 
anaerobic metabolism (von Haehling et al. 2017b). Aging leads to a cascade of changes that 
result in atrophy of type II fibers. These changes embrace alteration in neuromuscular 
junctions and peripheral motor neuron loss (von Haehling et al. 2017b).   
Fatty tissue infiltration plays a pivotal role in the structural muscle changes in sarcopenia. 
Besides, oxidative damage leads to mitochondrial dysfunction and an anabolic-catabolic 
imbalance (von Haehling et al. 2017b). Tumor necrosis factor (TNF) is associated with 
increased myocyte apoptosis, which could accelerate the process of muscle loss among HF 
patients (Figure 2, von Haehling et al. 2017b). Altogether, muscle loss occurs earlier than fat 
depletion during the progress of the chronic disease, leading to earlier deprivation of exercise 
tolerance than weight loss (von Haehling et al. 2017b). 
 
Figure 2. Wasting continuum in HF (von Haehling et al. 2017b). Usage with kind permission 
of the publisher (Springer Nature). 
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1.3.2 Treatment of wasting in HF 
No specific pharmacological therapy has been approved for wasting in HF (ESC 2016). 
Potential treatments include anti-myostatin antibodies, ghrelin-receptor agonists such as 
anamorelin, anti-inflammatory substances, and proteasome inhibitors (Saitoh et al. 2017, von 
Haehling et al. 2017b, Ishida et al. 2019). Appetite stimulants, nutritional supplementation, 
exercise training, testosterone, and other anabolic stimulants are other possible therapies, 
which need more clinical and safety evaluation (ESC 2016).  
Protein intake of 0.8 g/kg of body weight per day is recommended for HF patients (von 
Haehling et al. 2017b). However, in patients with muscle wasting, 1.0-1.2 g/kg of body 
weight per day might be indicated (von Haehling et al. 2017b, Payne-Emerson and Lennie 
2008). Similarly, a calorie intake of up to 35 kcal per kg of body weight per day should be 
safe (Okoshi et al. 2013). Cardiac rehabilitation programs are shown to improve functional 
performance and QOL and reduce hospital admission and mortality rates (Piepoli et al. 2004, 
von Haehling et al. 2017b).  
1.4 Measurement of  muscle mass 
The most common techniques to measure muscle mass include computed tomography (CT), 
magnetic resonance imaging (MRI), dual-energy X-ray absorptiometry (DXA), and 
bioelectric impedance (BIA, Buckinx et al. 2018). In contrast to other methods, DXA is more 
accessible, has lower radiation exposure (< 1 µSv for whole-body scans), and costs less 
(Buckinx et al. 2018). These advantages make DXA the most practical approach in 
sarcopenia research at present (Buckinx et al. 2018). Due to higher costs, sectional imaging 
techniques like CT and MRI are less applicable in daily clinical practice or even for research 
purposes (Buckinx et al. 2018).  
According to the European Society for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis (ESCEO) working group on frailty and sarcopenia, DXA is the gold standard 
for the assessment of muscle mass (Buckinx et al. 2018). The measured lean mass with DXA 
is highly comparable with the results of MRI and CT (Bredella et al. 2010, Maden-Wilkinson 
et al. 2013, Buckinx et al. 2018). The sum of skeletal muscle mass and all other organs is 
called total body lean soft tissue mass (Buckinx et al. 2018). The muscle mass in the arms 
and legs, representing about 75% of total body skeletal muscle mass, is termed Appendicular 
skeletal muscle mass (ASM, Buckinx et al. 2018). Appendicular skeletal muscle mass index 
(ASMI) is calculated by ASM divided by the squared height in meters (Buckinx et al. 2018).  
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Clark RV et al. (2017), in a study among 14 older patients including 13 healthy subjects and 
one HF patient, showed a strong correlation between creatine (methyl-d3) dilution in urine 
and the muscle mass estimate by MRI. They also observed the highest correlations between 
MRI and DXA. However, they reported a greater magnitude of bias DXA than with the D3-
creatine methods (Clark RV et al. 2017). Future studies with a greater number of patients are 
necessary to establish reliable laboratory screening tools for muscle wasting. 
 
Figure 3. Lunar iDXA, GE Healthcare. 
1.5 Assessment of  functional capacity 
The gold standard method for assessing functional capacity is the measurement of oxygen 
consumption (VO2) during CPET (Kaminsky and Tuttle 2015). The maximal oxygen uptake 
or peakVO2 is the main parameter (Kaminsky and Tuttle 2015). The Bruce protocol is the 
most frequently used method among different standardized treadmill protocols (Bruce et al. 
1963).  
Field tests like the 6-minute walk test (6MWT) are alternative methods for the assessment of 
exercise tolerance. Considerably, 6MWT does not accurately predict peakVO2 (Lucas et al. 
1999). Some reports have suggested that failure to achieve a certain distance, such as 300 m 
or 450 m on the 6MWT, has a prognostic value (Cahalin et al. 1996, Lewis et al. 2001). The 
American Thoracic Society (ATS) published a detailed guideline for performing a 6MWT, 
such as that it should be performed in a 30 m long hallway. However, the corridor's length 
and type (oval vs. back-and-forth) may interfere with the patient's performance (Kaminsky 
and Tuttle 2015).  
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The Short Physical Performance Battery (SPPB) consists of different functional measures, 
including the assessment of gait speed (4 m), strength (sit to stand), and balance (standing 
position). A composite score is formulated, in which higher scores demonstrate better 
functional performance (Kaminsky and Tuttle 2015). 
1.5.1 Analyzing muscular function 
Tests of muscular function are not well standardized in cardiology but have been extensively 
used in gerontology. The handgrip dynamometer is a practical method to evaluate muscular 
strength. Patients should squeeze the handle of the dynamometer as hard as they can for 3 
seconds (Kaminsky and Tuttle 2015). After an initial examination, the test is repeated two 
more times, and the best of the three tests is used (Kaminsky and Tuttle 2015). Lower limb 
muscle strength measurements usually include measurement of quadriceps strength (Cruz- 
Jentoft et al. 2010). Similar to handgrip strength, quadriceps strength has a prognostic value 
in the elderly. Muscle strength is shown to correlate with exercise intolerance (Hairi et al. 
2010, Rantanen et al. 1994; 2001, Visser et al. 2005), hospitalization (Cawthon et al. 2009), 
and mortality (Chan et al. 2014, Laukkanen et al. 1995, Newman et al. 2006). 
1.6  Assessment of  quality of  life (QOL) 
The negative impact of HF on health-related quality of life (HR-QoL) is well known (Juenger 
et al. 2002). Three main questionnaires have been validated to assess QOL in HF patients 
(Gallagher et al. 2019). Minnesota Living with Heart Failure Questionnaire (MLHFQ) 
includes 21 HF specific questions and analyzes HR-QoL during the last month. A higher 
score reflects a lower HR-QoL (Gallagher et al. 2019). The Kansas City Cardiomyopathy 
Questionnaire (KCCQ) consists of 23 specialized HF-related questions. It includes several 
aspects of patients' symptoms, self-efficacy, and physical and social limitations (Gallagher et 
al. 2019). A higher score is representative of a better QOL (Gallagher et al. 2019).  
The EuroQoL-5-Dimensions (EQ-5D) questionnaire consists of two sections. The first part, 
known as "health score", includes assessing the patient's mobilization, self-care, 
pain/discomfort, and depression/anxiety levels (Gallagher et al. 2019). The second part is a 
visual analog index score from 0 to 100, which provides a quantitative self-measured 
reflection of the patients' health (Gallagher et al. 2019). The health score is converted to a 
country-specific index.  A maximum health index score of 1 representing the perfect health 
status (Gallagher et al. 2019). The EQ-5D questionnaire is shown to have the highest total 




Figure 4. EQ-5D questionnaire (Schrag et al. 2000). Usage with kind permission of the 
publisher (BMJ). 
1.7 Cachexia vs. sarcopenia 
The prognostic importance of wasting is well established in other chronic diseases such as 
acquired immune deficiency syndrome (AIDS, Kotler et al. 1989) and cancer (Argilés et al. 
2014). Anker et al. (1997) showed higher mortality rates among HF patients with cachexia 
and, likewise, in patients with a peakVo2 < 14 mL/kg per min (Figure 5). Their study was 





Figure 5. Kaplan-Meier survival and cumulative hazard curves for 18-month survival (Anker 
et al. 1997). Usage with kind permission of the publisher (Lancet).  
 
Correspondingly, muscle wasting is known to decrease the functional capacity in both 
HFrEF and HFpEF patients (Fülster et al. 2013, Bekfani et al. 2016). In recently published 
data with prospectively enrolled ambulatory patients, muscle wasting was demonstrated as 
an independent predictor of death in chronic HF (Bielecka-Dabrowa et al. 2020). In 2017, 
Hajahmadi et al. demonstrated a shorter distance walked in 6MWT among patients with 
dilated cardiomyopathy (Hajahmadi et al. 2017).  
In addition, cachexia requires underlying chronic illness such as HF, whereas sarcopenia may 
appear as part of the normal aging process (Cruz-Jentoft et al. 2010, Alchin 2014). It is 
essential to be aware of this issue because the age difference could affect the functional 
capacity. Severe obesity is known to have negative functional impacts. However, in 
established severe obesity, additional weight gain does not significantly limit the functional 
capacity any further (Pataky et al. 2014). 
Sarcopenia is known to diminish not only exercise tolerance but also muscle strength in HF 
patients. Fülster et al. (2013) showed significantly lower peakVO2, and distance walked in 
6MWT among HF patients with sarcopenia.  
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Another crucial factor, which is usually missed in the routine assessment of HF patients is 
QOL. Muscle loss as a part of sarcopenia will lead to decreased muscle strength, which could 
indirectly harm the patient's QOL (Roubenoff et al. 1997).  
 
1.8 Aims 
The main goals of our study were as follows: To analyze body composition among patients 
with HF, to assess the prevalence of each type of wasting among HF patients, to investigate 
the overlap population (sarcopenia+cachexia) as an independent wasting category, and to 
compare the influence of different patterns of wasting on functional capacity, muscle 




2 Materials and methods 
2.1 Studies Investigating Co-morbidities Aggravating Heart Failure 
(SICA-HF)  
SICA-HF was a prospective, multinational, pathophysiological, and observational 
assessment of ambulatory HF patients (von Haehling et al. 2010). SICA-HF was funded by 
the European commission's Seventh Framework Program (FP7/2007-2013) under grant 
agreement no. 241558 (SICA-HF) and from the Russian Ministry of Science and Education 
within the FTP "R&D in priority fields of the S&T complex of Russia 2007-2012" under 
state contract number 02.527.11.0007 (von Haehling et al. 2010). The study was conducted 
under the Declaration of Helsinki principles and local/national regulations (von Haehling et 
al. 2010). National and local ethics committees reviewed and approved the study protocol 
(von Haehling et al. 2010). All patients signed a written informed consent before inclusion 
or participated in any study-related examination (von Haehling et al. 2010). The inclusion 
and exclusion criteria of the SICA-HF are summarized in Table 2.  
Table 2. Inclusion and exclusion criteria for SICA-HF (von Haehling et al. 2010). 
Inclusion criteria Exclusion criteria 
 
- Clinical diagnosis of HF. 
- Objective evidence of cardiac dysfunction, as 
evidenced by at least one of the following: 
- Left ventricular EF ≤ 40%. 
- Left atrial dimension > 4.0 cm (or > 2.5 cm/m 
in height).  
- N-terminal pro B-type natriuretic peptide 
hormone (NT-proBNP) > 400 pg/ml (> 47.3 
pmol/l) (or B-type natriuretic peptide 
hormone (BNP) > 150 pg/ml). 
- Age > 18 years. 
- Willingness to provide informed consent . 
 
 
- Previous heart transplantation. 
- History of unstable angina, myocardial infarction, 
stroke, cardiovascular revascularization, or open 
abdominal surgery within six weeks before the 
planned baseline visit. 
- Known pregnancy. 
- Patients on hemodialysis at baseline. 
- Unable to understand and comply with protocol or 
give informed consent. 
 
 
According to the national kidney foundation report (2002), patients with a glomerular 




All patients underwent a transthoracic echocardiogram (TTE). The biplane Simpson method 
was used to calculate the left ventricular EF. In this technique, the left ventricular blood 
volume is measured in the end-diastole by tracings the blood-tissue interface in both apical 
four- and two-chamber views. Left ventricular length is also determined through a 
perpendicular line based on the middle of the mitral line at the cardiac apex. The EF of the 
left ventricle will be calculated automatically (Lang et al. 2015).  
2.2 Study population 
Overall, 207 ambulatory male patients with symptomatic HF with inclusion and exclusion 
criteria, as mentioned above, were enrolled in a prospective analysis. Both HFrEF and 
HFpEF patients were recruited into the study starting March 2010 until April 2012 at the 
Charité Universitäsmedizin, Berlin, Germany (Fülster et al. 2013). Being aware of the high 
prevalence of HFpEF among female patients, SICA-HF initially embraced 20.5% women. 
Due to the small prevalence of female patients, especially in the overlap group, we chose to 
exclude female patients solely for this analysis.   
2.3 Body composition 
The GE Lunar Prodigy DXA scanner was used to measure different parameters for body 
composition. The assessments were applied for total and individual body parts. The data 
analysis was performed with GE Lunar Encore software (Madison, WI, USA, Fülster et al. 
2013), which automatically generates tables and diagrams with the possibility to compare the 
results with normal ranges for a particular age and gender. Regular controls and calibrations 
were performed according to the manufacturer's instructions. No metal objects like mobile 
phones, watches, or jewelry were allowed during the examination. As demonstrated in Figure 
3, the patients had to lie on their back on the device surface. The scanner moves slowly over 
the patient's body. The scan time was usually about 15-20 minutes. Both fat mass and lean 




Figure 6. An example of a DXA result from SICA-HF. 
2.4 Functional capacity and quality of  life 
An isokinetic dynamometer (Multitrace 2, Lectromed, Jersey, Channel Islands) was used to 
assess quadriceps strength (Fülster et al. 2013). The maximal strength was measured in a 
sitting position with both legs hanging freely as the ankle stabilized by a pressure transducer. 
The best of the three measurements was reported (Fülster et al. 2013). The handgrip strength 
was evaluated using a handgrip dynamometer (Saehan Corporation Korea Hydraulic Hand 
Dynamometer, model SH5001, Fülster et al. 2013), the highest measured value was reported 
respectively (Fülster et al. 2013). The Bruce protocol was used to perform CPET on a 
treadmill (Bruce et al. 1963). Ventilation parameters such as peakVO2 (mL/min), anaerobic 
threshold, and carbon dioxide production (VCO2 in mL) were measured (Fülster et al. 2013). 
Due to independence from the voluntary effort and substantial prognostic value, peakVO2 
and ventilatory patterns play a crucial role in estimating functional capacity (Fülster et al. 
2013, Malhotra et al. 2016).  
The 6MWT was performed according to the official statement of the American Thoracic 
Society (ATS pulmonary function 2002). The SPPB-test was performed using three subtests, 
including the standing balance test, walking speed test, and the sit-to-stand test. A maximum 
of 12 points demonstrates the best possible functional performance (Guralnik et al. 1994, 
Fülster et al. 2013).  
15 
 
Patients were asked to fill out the EQ-5D questionnaire. This questionnaire was used to 
calculate the EQ-5D index score.  
2.5 Definitions and grouping 
According to previously published international consensus, sarcopenia was defined as muscle 
mass two standard deviations (SD) below the mean of a healthy young reference group 18-
40 years old (ASMI < 7.26 kg in men, < 5.45 kg in women, Morley et al. 2011, Gallagher et 
al. 1997). 
Between the different cut-offs for cachexia, we chose a non-edematous, non-intentional 
weight loss ≥ 6% over at least one year as our main cut-off for cachexia because it had the 
highest prognostic value as compared to other possible choices (Anker et al. 2003).  
Patients who fulfilled the criteria for sarcopenia but without associated cachexia were labeled 
as "sarcopenic HF". Patients with cachexia without a significant muscle loss were named as 
"cachectic HF". Also, patients with characteristics of both sarcopenia and cachexia were 
labeled as "overlap group". Finally, HF patients without sarcopenia or cachexia were included 
as the "control group". 
2.6 Statistical analysis 
Statistical Package for the Social Sciences (SPSS Statistics for Windows, Version 24.0, IBM 
Corp. Armonk, NY, USA) applied to analyze the results. Analysis of variance (ANOVA) was 
used to compare the basic characteristics of our four included groups. The analysis of 
covariance (ANCOVA) with Tukey's post hoc test was implemented to compare the 
functional capability, muscle strength, and QOL. Being aware of the possible interference of 
other limiting factors on functional parameters, we checked the assumption of homogeneity 
of regression slopes for all variables measured at baseline. Only age, BMI, and NYHA-
classification have met this assumption. Functional parameters, muscle strength, and QOL 
were adjusted for the mentioned covariates, which met the ANCOVA's assumption. The 







3.1 Clinical Characteristics 
We prospectively enrolled 207 male outpatients with chronic HF. A total of 154 (74.4%) 
patients presented with HFrEF and 53 (25.6%) with HFpEF. The mean age of the 
participants was 67.3±10.1 years. TTE showed an average EF of 36.9±12.5%. No patient 
with NYHA classification IV was recruited; most of the included patients had NYHA 
classification II-III. The average measured BMI was 28.8±5.0 kg/m2. Ischemic HF was 
determined in 59.9% of patients and atrial fibrillation in 39.1%.  In addition, 38.2% of the 
participants had diabetes. Among our HF patients, 38.6% had CKD, but the patients with 
ongoing hemodialysis at baseline were excluded. Hypertension was determined in 59.4% and 
hyperlipidemia in 51.7% of our study population. The prevalence of anemia among our 
patients was 32.4%, whereas the hemoglobin level was significantly lower in the overlap 
group vs. the control group. 
The sarcopenic HF group, as expected, had the highest age vs. cachectic HF and the control 
group (p < 0.05, Table 3). Furthermore, the overlap group showed the lowest BMI vs. the 
cachectic HF and the control group (p < 0.05, Table 3). 
Among the measured inflammatory parameters, only the overlap group showed significantly 
lower results in IL-6 vs. the control group (without wasting, p < 0.05, Table 3). However, no 
significant differences were determined in IL-1 and TNF results.  
Considering medication, 95.2% of participants were treated with Angiotensin-converting 
enzyme inhibitors (ACE inhibitors) or angiotensin II receptor type 1 antagonists (AT 1 
antagonists) and 91.3% with beta-blockers, respectively. Furthermore, 59.9% were treated 
with thiazide or loop diuretics and 21.3% with Mineralocorticoid Receptor Antagonists 
(MRAs). Considerably,  no significant difference was observed in pharmacological therapy 




Table 3. Baseline characteristics. ACE-inhibitors: Angiotensin-converting enzyme 
inhibitors, AT1-antagonists: angiotensin II receptor type 1 antagonists, BMI: body mass 
index, CKD: chronic kidney disease, HF: heart failure, HFpEF: heart failure with preserved 
ejection fraction, HFrEF: heart failure with reduced ejection fraction, hsCRP: high-sensitivity 
C-reactive protein, IL-1: interleukin-1, IL-6: interleukin-6, EF: ejection fraction, MRA: 
Mineralocorticoid Receptor Antagonists, NYHA: New York Heart Association 
classification, TNF: tumor necrosis factor. §: vs. control group, †: vs. sarcopenic HF group, 
*: vs. cachectic HF group. Each symbol denotes p < 0.05. Symbols in brackets denote a trend 
with p < 0.1. The inflammatory parameters such as TNF, interleukin-1β (IL-1β), or 
interleukin-6 (IL-6) were reported as the median and interquartile range (Emami et al. 2018). 
Usage with kind permission of the publisher (John Wiley and Sons). 






 (n = 207) (n = 138) (n = 25) (n = 30) (n = 14)  




2.3 ± 0.6 2.2 ± 0.6 2.2 ± 0.6 2.4 ± 0.7 2.6 ± 0.6 0.09 
BMI (kg/m2) 28.8 ± 5.0 30.1 ± 4.8 28.7 ± 4.3 25.7 ± 4.4 § 24.0 ± 3.6 § * < 0.001 
Weight change 
during the past 
12 months (kg) 
-0.2 ± 7.3 +2.0 ± 6.5 
-9.5 ± 6.4 § 
† 
+0.8 ± 2.9  -7.6 ± 4.2 § † < 0.001 
EF (%) 36.9 ± 12.5 38.7 ± 12.8 31.2 ± 9.7 § 36.7 ± 12.4 28.5 ± 7.2 § 0.002 
HFrEF/HFpEF 
(%) 
74.4/25.6 68.8/31.2 92.0/8.0 73.3/26.7 100/0 0.09 
Ischaemic HF 
(%) 
59.9 56.5 52.0 70.0 85.7 0.3 
Hypertension 
(%) 
59.4 58.7 72.0 46.7 71.4 0.009 
Hyperlipidemia 
(%) 












 (n = 207) (n = 138) (n = 25) (n = 30) (n = 14)  
Diabetes (%) 38.2 40.6 36.0 36.7 21.4 0.6 
CKD (%) 38.6 37.0 44.0 43.3 35.7 0.8 
Anemia (%) 32.4 25.4 40.0 50.0 50.0 0.02 
Atrial fibrillation 
(%) 
39.1 37.7 40 36.7 57.1 0.8 
Mild peripheral 
edema (%) 
57.0 60.1 56.0 53.3 35.7 0.2 
hsCRP (mg/dL) 3.0 ± 2.3 2.8 ± 2.1 3.2 ± 2.6 3.4 ± 2.6 3.6 ± 2.0 0.6 
IL-1 (pg/mL) 
0.01 (0.01 - 
0.08) 
0.01 (0.01 - 
0.07) 
0.01 (00.01 - 
0.07) 
0.03 (0.01 - 
0.1) 
0.01 (0.01 - 
0.1) 
0.8 
IL-6 (pg/mL) 1.2 (0.3 - 2.9) 
1.0 (0.09 - 
2.1) 
1.2 (0.3 - 
2.9) 
1.8 (0.8 - 4.0) 
(§) 
3.7 (1.6 - 6.1) § 0.01 
TNF (pg/mL) 
0.06 (0.06 - 
1.9) 
0.06 (0.06 - 
1.8) 
0.06 (0.06 - 
1.9) 
1.0 (0.06 - 2.9) 0.2 (0.06 - 2.9) 0.8 
Creatinine 
(mg/dL) 
1.2 ± 0.4 1.2 ± 0.4 1.3 ± 0.6 1.2 ± 0.5 1.3 ± 0.4 0.8 
Hemoglobin 
(g/dL) 
13.6 ± 1.5 13.7 ± 1.5 13.5 ± 1.8 13.3 ± 1.3 12.6 ± 1.4 § 0.02 
Albumin 
(mg/dL) 
36.9 ± 12.5 37.7 ± 3.6 37.6 ± 4.1 36.1 ± 4.1 35.2 ± 3.5 0.06 














95.2 95.7 96.0 93.3 92.9 0.9 
Beta-blocker (%) 91.3 90.6 88.0 96.7 92.9 0.6 
Thiazide/Loop 
diuretics (%) 
59.9 60.9 72.0 43.3 64.3 0.2 
MRAs (%) 21.3 22.5 16.0 16.7 28.6 0.7 
 
Sarcopenia without concomitant cachexia was present in 14.5% (sarcopenic HF group). 
Isolated cachexia without associated sarcopenia was observed in 12.1% (cachectic HF 
group). In addition, 6.7% showed the characteristics of both sarcopenia and cachexia 
(overlap group). Overall, 21.3% presented with sarcopenia (sarcopenic HF and overlap 




Figure 7. Prevalence of sarcopenia, cachexia, and their overlap. The prevalence of sarcopenia 
and cachexia in our study was 21.3% and 18%, respectively (Emami et al. 2018). Usage with 
kind permission of the publisher (John Wiley and Sons). 
3.2 Functional capacity, muscle strength & QOL 
The lowest results for functional capacity, muscle strength, and QOL were observed in the 
patients with sarcopenia vs. the control group without wasting. To be more exact, the overlap 
group showed the lowest values for handgrip strength, 6MWT, peakVO2, and SPPB test vs. 
the control group (p < 0.05, Table 4 & Figure 8).  Likely, the overlap group had lower EQ-
5D index scores vs. the control group (p < 0.05, Table 4). In addition, the weakest quadriceps 
strength were observed in the overlap group (p < 0.05, Table 4 & Figure 8). 
The sarcopenic HF was observed to have significantly lower results for muscle strength, 
distance walked in 6MWT, peakVO2, SPPB score, and QOL index score vs. the control group 
(p < 0.05, Table 4 & Figure 8). Both the sarcopenic HF and overlap groups indicated shorter 
distance walked in 6MWT vs. the control group, but this effect was more prominent in the 
sarcopenic HF group (p < 0.01 vs. p < 0.05).  
All three sarcopenic HF, cachectic HF, and overlap groups, showed significantly lower 
quadriceps strength and peakVO2 vs. the control group. However, the most significant lower 
results were observed among the overlap group (p < 0.001). Both the functional and the 
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QOL analyses were adjusted for age, BMI, and NYHA classification, as these were the only 
significant parameters. 
 
Table 4. Functional capacity, muscle strength, and QOL. 6MWT: 6-minute walk test, EQ-
5D: EuroQol-5 Dimensions, HF: heart failure, peakVO2: peak oxygen uptake, SPPB: Short 
Physical Performance Battery. Functional performance, muscle strength & QOL results are 
adjusted for age, BMI, and NYHA classification. §: vs. control group; †: vs. sarcopenic HF 
group, *: vs. cachectic HF group. Each symbol represents p < 0.05. Symbols in brackets 
indicate a trend with p < 0.1 (Emami et al. 2018). Usage with kind permission of the publisher 
(John Wiley and Sons). 
 all Control 
Cachectic 
HF 
Sarcopenic HF Overlap p-value 














455 ± 129 444 ± 88 362 ± 138 § 358 ± 136 § 0.02 
PeakVO2 
(mL/min/kg) 
17.7 ± 4.9 18.8 ± 4.7 16.5 ± 4.7 § 15.3 ± 4.3 § 12.7 ± 4.2 § (*) (†) < 0.001 










Figure 8. Functional capacity & muscle strength. (A) Handgrip strength, (B) Quadriceps 
strength, (C) 6-minute walk test, and (D) Peak oxygen uptake(peakVO2) in the four study 
groups. HF: Heart failure. §: vs. control group, †: vs. sarcopenic HF group, *: vs. cachectic HF 
group. One symbol represents p < 0.05, two symbols p < 0.01, three symbols p < 0.001. 
Symbols in brackets indicate a trend with p < 0.1 (Emami et al. 2018). Usage with kind 
permission of the publisher (John Wiley and Sons). 
3.3 Body composition 
As compared to the control group, the overlap group showed significantly lower results for 
total, arms, and legs fat mass (p < 0.05 for all measures). In addition, the overlap group 
demonstrated lower truncal fat mass vs. all other groups (p < 0.05, Table 5). The total fat 
mass was also significantly lower in the overlap group vs. the sarcopenic HF group (p < 0.05, 
Table 5).  
As expected, the sarcopenic HF group showed a lower lean mass in total and in other 
measured body parts vs. both cachectic HF and control group (p < 0.05, Table 5). The overlap 
group demonstrated similar impacts on most measurements except for truncal lean mass.  
ASM, as measured by the sum of lean muscle mass results of both arms and legs, was 




Table 5. Body composition. ASM: appendicular skeletal muscle mass, ASMI: appendicular 
skeletal muscle mass index, HF: heart failure. §: vs. control group, †: vs. sarcopenic HF group, 
*: vs. cachectic HF group. Each symbol indicates p < 0.05. Symbols in brackets represent a 
trend with p < 0.1 (Emami et al. 2018). Usage with kind permission of the publisher (John 
Wiley and Sons). 
  all Control 
Cachectic 
HF 
Sarcopenic HF Overlap p-value 
  (n = 207) (n = 138) (n = 25) (n = 30) (n = 14)  
  Fat (kg)            
  - arms 2.3 ± 0.9 2.4 ± 0.9 2.1 ± 0.8 2.0 ± 0.8 (§) 1.6 ± 0.9 § 0.001 
  - legs 7.6 ± 3.0 7.9 ± 2.9 6.7 ± 2.3 7.5 ± 3.5 5.4 ± 2.1 § 0.01 
  - trunk 16.8 ± 6.1 18.0 ± 5.5 15.7 ± 5.9 15.5 ± 7 .0 10.2 ± 4.5 § * † < 0.001 
  - total 27.4 ± 9.7 29.1 ± 9.0 24.8 ± 9.1 25.9 ± 11.1 16.8 ± 7.3 § † (*) < 0.001 
  Lean mass (kg)            
  - arms 6.3 ± 1.1 6.5 ± 0.9 6.7 ± 1.0 5.4 ± 0.8 § * 4.9 ± 0.5 § * < 0.001 
  - leg 18.9 ± 3.1 19.7 ± 2.7  19.9 ± 2.7 15.9 ± 1.9 § * 15.3 ± 2.2 § * < 0.001 
  - trunk 28.5 ± 5.1 29.2 ± 5.1 29.7 ± 4.3 25.7 ± 4.9 § * 26.7 ± 3.4 0.001 
  - total 57.9 ± 8.5 59.0 ± 8.1 60.6 ± 7.6 51.0 ± 6.8 § * 50.2 ± 5.4 § * < 0.001 
  ASM (kg) 24.9 ± 3.9 25.9 ± 3.4 26.1 ± 3.4 20.9 ± 2.4 § * 19.8 ± 2.8 § * < 0.001 
  ASMI 8.0 ± 1.1 8.4 ± 0.8 8.5 ± 0.8 6.8 ± 0.5 § * 6.5 ± 0.6 § * < 0.001 
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3.4 Alternative analyses 
The overlap group embraces both the characteristics of sarcopenia and cachexia. It showed 
promising results in our functional capacity and QOL measurements. To reach a more 
comprehensive understanding of this group, we designed two alternative analyses.  
The overlap group was joined in the first alternative grouping into the cachectic HF group 
to shape a combined "cachexia group". The other two groups remained unchanged. The new 
cachexia group showed significantly lower results vs. the control group for quadriceps 
strength and peakVO2 (p < 0.05, Table 6) but could not demonstrate a significant difference 
in QOL indices.  Similar to the primary analysis, the sarcopenic HF patients showed lower 
results for functional capacity and QOL vs. the control group (all p < 0.05, Table 6).  
Table 6. First alternative analysis. The overlap group was included in the cachexic HF group 
as a combined "cachexia group". EQ-5D: EuroQol-5 Dimensions, HF: heart failure, 6MWT: 
6-minute walk test, SPPB: Short Physical Performance Battery, peakVO2: peak oxygen 
uptake. Functional performance, muscle strength & QOL models were adjusted for age, 
BMI, and NYHA classification. §: vs. control group, *: vs. cachexia group. Each symbol 
indicates p < 0.05. Symbols in brackets represent a trend with p < 0.1 (Emami et al. 2018). 
Usage with kind permission of the publisher (John Wiley and Sons). 
 all Control cachexia sarcopenic HF p-value 
 (n = 207) (n = 138) (n = 39) (n = 30)  
Handgrip strength (kg) 39.8 ± 11.2 41.8 ± 10.5 38.1 ± 13.4 33.2 ± 8.5 § 0.04 
Quadriceps strength 
(kg) 
39.9 ± 13.3 43.2 ± 12.7 33.7 ± 13.9 § 34.1 ± 10.5 (§) 0.002 
6MWT (m) 438 ± 136 455 ± 129 410 ± 115 (§) 362 ± 138 § 0.02 
PeakVO2 
(mL/min/kg) 
17.7 ± 4.9 18.8 ± 4.7 15.0 ± 1.1 § 15.3 ± 4.3 § < 0.001 
SPPB score 10.5 ± 2.0 10.8 ± 1.7 10.0 ± 2.3 (§) 9.4 ± 2.6 § 0.03 




We included the overlap group in the second optional analysis into the sarcopenic HF group 
to shape the "muscle wasting group". The other two groups, including cachectic HF and 
control groups, remained unchanged. As compared to the control group, all of the functional 
parameters, including peakVO2, 6MWT distance, SPPB score, and muscle strength, were 
significantly lower in the muscle wasting group. Considerably, the muscle wasting group 
presented with a lower QOL vs. both other groups  (p < 0.05 for all, Table 7).  
It has to be kept in mind that none of the cachectic groups, including the unified cachexia 
group in the first analysis and the cachexic HF group in the second analysis, could 
demonstrate any significant impact on QOL indices. This effect was only observed among 
groups with sarcopenia. Furthermore, lower SPPB scores were only observed among 




Table 7. Second alternative analysis. The overlap group was included in the sarcopenic HF 
group to shape a unified "muscle wasting group". EQ-5D: EuroQol-5 Dimensions, HF: 
heart failure, 6MWT: 6-minute walk test, SPPB: Short Physical Performance Battery, 
peakVO2: peak oxygen uptake. All functional and QOL models were adjusted for BMI, age, 
and NYHA classification. §: vs. control group, *: vs. cachectic HF group. Each symbol 
indicates p < 0.05. Symbols in brackets represent a trend with p < 0.1 (Emami et al. 2018). 
Usage with kind permission of the publisher (John Wiley and Sons). 
  all Control cachectic HF muscle wasting p-value 
 (n = 207) (n = 138) (n = 25) (n = 44)  
Handgrip 
strength (kg) 
39.8 ± 11.2 41.8 ± 10.5 42.1 ± 13.8 32.8 ± 9.1 § (*) 0.009 
Quadriceps 
strength (kg) 
39.9 ± 13.3 43.2 ± 12.7 38.7 ± 14.4 (§) 31.1 ± 10.4 § 0.002 
6MWT (m) 438 ± 136 455 ± 129 444 ± 88 360 ± 135 § 0.007 
PeakVO2 
(mL/min/kg) 
17.7 ± 4.9 18.8 ± 4.7 16.5 ± 4.7 § 14.4 ± 4.4 § < 0.001 
SPPB score 10.5 ± 2.0 10.8 ± 1.7 10.7 ± 1.6 9.3 ± 2.6 § (*) 0.009 






This is the first study to compare different types of body wasting in patients with HF.  In a 
cross-sectional analysis in the framework of SICA-HF, we found sarcopenia in 21.3% of our 
HF patients. In this context, 14.5% fulfilled sarcopenia's definition without associated 
cachexia (sarcopenic HF group). 12.1% presented with cachexia without concomitant 
sarcopenia (cachectic HF group). Furthermore, 6.8% of patients demonstrated the 
characteristics of both sarcopenia and cachexia, denoted as the overlap group.  
HF patients with sarcopenia had significantly lower muscle strength, functional capabilities, 
and QOL. Meanwhile, the overlap group had the weakest results vs. the control group. This 
effect was absent among other groups without sarcopenia.  
HF patients with sarcopenia indicated a significantly lower QOL with or without the overlap 
population. This effect was absent in the patients with cardiac cachexia even after combining 
with the overlap group.  
HF is not the only chronic disease to induce sarcopenia. Many other chronic disorders are 
reported to involve muscle tissue. Foley et al. (2007) reported a prevalence of 31.7% for 
sarcopenia among CKD patients; they also found a lower likelihood of developing sarcopenia 
in physically active CKD patients. In addition, diabetic patients were found to have a three 
times higher risk of developing sarcopenia than the average population (Kim et al. 2010). 
Kim et al. showed a prevalence of 15.7% for sarcopenia among their diabetic patients. In 
2015, Jones et al. studied 622 stable COPD patients with 14.5% prevalence for sarcopenia. 
Sarcopenic COPD patients in this study were demonstrated to have lower exercise capacity 
(Jones et al. 2015). 
Cachexia was first acknowledged as a prognostic risk factor in HF patients in 1997. Anker et 
al. showed a prevalence of 16% for cachexia in their HF patients. They demonstrated a 
significantly higher mortality rate in cachectic HF patients at 18 months of follow-up vs. the 
non-cachectic control group. Furthermore, cachectic HF patients showed significantly lower 
values for peakVO2. However, muscle strength and QOL were not concretely assessed in 
this study. The prevalence of cachexia of 19% in our analysis was similar to Anker at al. 
results. In our study, all groups with wasting showed lower peakVO2 vs. the control group. 
We did not assess the long time survival of the patients, though. 
In a very recent prospective study with 268 patients, von Haehling et al. showed muscle 
wasting to be an independent predictor of death among ambulatory HF patients (von 
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Haehling et al. 2020). This effect was discussed to be more pronounced in HFrEF than 
HFpEF patients (von Haehling et al. 2020). A lower prevalence of muscle wasting in their 
study (17.5%) could be due to the inclusion female patients. This study confirmed that not 
only cachexia but also sarcopenia has a prognostic impact on chronic HF. 
Muscle wasting was shown to be present in 47.3% of HF patients with non-ischemic dilated 
cardiomyopathy (Hajahmadi et al. 2017). Compared to our analysis, a higher prevalence of 
muscle wasting in the Hajahmadi et al. study could be due to the inclusion of only HFrEF 
patients. Since dilated cardiomyopathy is a genetically determined disease, it cannot be 
excluded that some of these patients had a muscular disease such as myositis. Hajahmadi et 
al. reported a significantly shorter distance walked in 6MWT among HF patients with muscle 
wasting (Hajahmadi et al. 2017); this was in agreement with our study. HF patients with 
sarcopenia in our analysis also indicated weaker results in 6MWT. However, this effect was 
not observed among cachectic HF patients.   
In the Studies of Left Ventricular Dysfunction (SOLVD) with 1929 HF patients, Anker et 
al. (2003) discussed a weight loss ≥ 6% as the strongest predictor of impaired survival. Other 
cut-off values for weight loss, including ≥ 5.0%, ≥ 7.5%, ≥ 10.0%, and ≥ 15.0%, did not 
show the same prognostic significance (Anker et al. 2003). Based on these results, we took 
the 6% cut-off to define cachexia among our HF patients. The prevalence of cachexia in 
Anker et al. study was 36%. A higher prevalence of cachexia in Anker et al. data could result 
from the more extended follow-up (35±13 months). The time window to define cachexia in 
our study was 12 months. 
Fülster et al. (2013), with the same SICA-HF database, studied HF patients' body 
composition with a DXA scanner. They found a prevalence of 19.5 % for muscle wasting 
among their 200 ambulatory HF patients. Similar to our analysis, they showed reduced 
exercise capacity and muscle strength among HF patients with muscle wasting (Fülester et 
al. 2013). However, they did not address the cardiac cachexia and its overlap with muscle 
wasting. Furthermore, in this study, the changes in the QOL were not discussed.  
Later in another prospective analysis with 117 HF patients, Bekfani et al. (2016) showed a 
prevalence of 19.7% for muscle wasting among HF patients with HFpEF. This study 
confirmed that HFpEF patients with muscle wasting tend to have significantly lower exercise 
capacity, muscle strength, and QOL. Bekfani et al. highlighted the importance of early 
diagnosis of muscle wasting in HFpEF patients. In our analysis, we included both HFrEF 
and HFpEF patients. However, we separated the cachectic and sarcopenic patients and 
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compared their impact on different aspects of functional capacity, muscle strength, and 
QOL.  
In another study, in the framework of SICA-HF with 228 HF patients, Dos Santos et al. 
(2016) discussed the impact of endothelial dysfunction on functional capacity among HF 
patients with sarcopenia. They discussed a blunted vasodilatation in sarcopenic patients, 
which was associated with lower functional capacity (Dos Santos et al. 2016). This study 
implemented the same database as our analysis with the inclusion of female patients, but they 
did not assess the SPPB-score, muscle strength, or QOL. Furthermore, they did not address 
cachectic patients and the potential overlap population separately. 
In their cross-sectional study, Canteri et al. (2019) reported a prevalence of 30.4% for 
sarcopenia among HFrEF patients. The higher prevalence of sarcopenia in this study could 
be emerged due to the exclusion of HFpEF patients. Furthermore, a smaller study 
population and different anthropometric profiles could contribute to this difference. In 
concordance with our analysis, they showed lower handgrip strength in men with sarcopenia 
vs. the control group. However, the same effect could not be determined in female patients 
with sarcopenia.  
Lower AMSI was recently discussed as a prognostic factor among patients with ST-Elevation 
Myocardial Infarction (STEMI, Sato et al. 2020). Sato et al. demonstrated a lower ASMI to 
be independently associated with a higher risk of primary composite events. Similar to our 
study, they found that the patients with lower ASMI were older and had lower BMI and 
hemoglobin levels (Sato et al. 2020). In contrast to our analysis, Sato et al. used a lower cut-
off for ASMI than the cut-off determined by the Asian Working Group for Sarcopenia 
(AWGS, ≤ 6.64 kg/m2 for men and ≤ 5.06 kg/m2 for women).  
A cross-sectional study with 155 HF patients Nakano et al. (2020) indicated an association 
between loop diuretics therapy and smaller thigh circumference. They implemented tight 
circumference instead of DXA to define muscle loss. Arm or thigh circumference could be 
an acceptable or practical reflection of muscle mass, but they are known to have lower 
accuracy than DXA. In our analysis, 59% of patients were treated with a loop or thiazide 
diuretic. No significant difference in the application of loop diuretics was found, though 
(Table 3). 
Clark AL et al. (2017), in a prospective study with 2289 patients (COPERNICUS trial), 
reported a partial reversal of cachexia in severe HF under therapy with carvedilol. In 
concordance to our research, they used the same 6% cut-off to define cardiac cachexia. 
The carvedilol group showed a lower likelihood of developing a significant weight loss 
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(>6%) vs. the placebo group. Their study did not mainly address sarcopenia or exercise 
capacity.  
In a randomized trial with 237 patients, Nipp et al. (2017) showed lower QOL and a higher 
risk of depression among sarcopenic patients with advanced lung cancer. Nipp et al. used 
the skeletal muscle cross-sectional area (CSA) at the level of the third lumbar vertebrae, 
measured during an abdominal CT scan, to define sarcopenia (< 55 cm2 for men and < 39 
cm2 for women, Fearon et al. 2011). The prevalence of sarcopenia among their cancer 
population was 55.3% (Nipp et al. 2017). A very high prevalence of sarcopenia, particularly 
in lung cancer patients, is well known (Buentzel et al. 2019). Assessment of sarcopenia in 
follow-ups CT scans is applicable among cancer patients. However, due to high radiation 
exposure and cost, a CT scan cannot be a suitable option for HF patients.  
Another ongoing debate related to sarcopenia is frailty. Frailty is defined as an increased age-
dependent vulnerability (Bielecka-Dabrowa et al. 2020). Due to higher rates of falls, 
institutionalization, and hospitalization, frailty is associated with poor prognosis and higher 
mortality rates (Bielecka-Dabrowa et al. 2020, Fried et al. 2001). Frailty is discussed to be a 
result of loss in muscle mass and bone mineral density (BMD, Bielecka-Dabrowa et al. 2020). 
According to ESC, frailty in HF is defined as a multidimensional dynamic state, independent 
of age, which makes the HF patient more vulnerable to stressors (Vitale et al. 2019, Bielecka-
Dabrowa et al. 2020). Frailty is shown to be associated with a 92% higher risk for emergency 
department visits and a 65% higher risk for hospitalization (McNallan et al. 2013). Cachexia 
could involve different body compartments, including fat-free mass, fat mass, and bone mass 
(Bielecka-Dabrowa et al. 2020). In our analysis, we did not address the frailty or changes in 
BMD, but cachectic HF patients showed lower exercise tolerance without a significant loss 
in muscle mass.   
Muscle wasting is expected to occur among healthy elderly subjects as a result of the aging 
process (Bielecka-Dabrowa et al. 2020). However, chronic diseases like HF can contribute 
to the process of muscle loss, which can explain the higher prevalence of sarcopenia in 
HFrEF (19.5%, Fülster et al. 2013) and HFpEF (19.7%, Bekfani et al. 2016). The higher 
prevalence of sarcopenia in chronic disease could be due to inflammatory responses. IL-6 
has been viewed primarily as an inflammatory factor (Bielecka-Dabrowa et al. 2020). IL-6 
promotes glucose uptake and fatty acid oxidation locally in the muscle, increases fatty acid 
release from adipocytes, and stimulates the secretion of glucagon-like peptide-1 (GLP-1, 
Bielecka-Dabrowa et al. 2020). In our analysis, IL-6 levels were significantly higher in the 
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overlap group vs. the control group (p < 0.05, Table 3). Other inflammatory parameters like 
IL-1β or TNF didn't show the same significance.  
Our study highlights the impacts of muscle wasting on functional capacity and QOL among 
HF patients. Cachexia has demonstrated some negative influence on functional performance, 
but this effect was less significant. Sarcopenic patients can lose lean muscle even without a 
substantial weight loss. On the other hand, cachexia can occur due to loss in skeletal muscle, 
bone, or adipose tissue. Early stages of sarcopenia with mitochondrial dysfunction, fiber 
transformation, and fatty infiltration could manifest without an associated weight loss (von 
Haehling et al. 2017b). The beginning impacts of sarcopenia could emerge without any 
relevant changes in patients' BMI.   
On the other side of the spectrum, obesity is a known independent risk factor for chronic 
HF (Horwich et al. 2018). During the last decade, obesity has been shown to have a 
paradoxical significant survival benefit in chronic HF (Simonenko 2019, Anker and von 
Haehling 2011). Due to higher BMI, obese patients may experience more limitations in their 
exercise tolerance and QOL, encouraging them to present themselves earlier for therapy. It 
is assumed that obese patients have a lower circulatory BNP and an attenuated response to 
the renin-angiotensin-aldosterone system (Horwich et al. 2018, Lavie et al. 2009, Mehra et al. 
2004). These factors contribute to maintain higher blood pressures and preserve renal 
circulation (Horwich et al. 2018). Under these circumstances, cardioprotective medications 
such as beta-blockers, ACE-inhibitors, and neprilysin inhibitors could be applied in higher 
doses (Horwich et al. 2018). The latest ESC guidelines for HF does not include a weight loss 
program for patients with non-morbid obesity (BMI < 35 kg/m2, ESC 2016). The obesity 
paradox underscores this assumption that BMI cannot adequately represent the body 
composition among HF patients.    
Muscle wasting in HF has profound impacts on patients' exercise tolerance and QOL. 
Sarcopenic patients tend to be physically dependent on others in later life (Dos Santos et al. 
2017). In the latest ESC guidelines, sarcopenia is acknowledged as a co-morbidity of HF. 
Early diagnosis and management of both sarcopenia and cachexia in HF are modulatory. As 
mentioned before, no particular pharmacologic therapies for sarcopenia have been approved 
yet (ESC 2016).  
Being aware of the high prevalence of HFpEF among women, SICA-HF originally included 
20.5% female patients. The main limitation of our analysis was the low prevalence of females 
with sarcopenia and cachexia. For example, no female patient was present in our overlap 
group, so that we excluded females from our analysis. It has been long established that 
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testosterone is a potent anabolic factor for maintaining muscle mass (Anderson et al. 2017). 
Testosterone promotes protein synthesis and muscular regeneration, which is abundant in 
healthy young men (Anderson et al. 2017). During aging or other chronic disorders, 
testosterone deficiency leads to a more robust catabolic response in men than women 
(Anderson et al. 2017). On the other hand, estrogens may have a protective effect on 
preserving muscle mass and function due to anti-inflammatory and anti-catabolic effects 
(Anderson et al. 2017). These changes could explain the smaller population of females with 
muscle wasting in our analysis. A prospective study among women with sarcopenic HF is 
currently underway. 
Another limitation of our analysis was the small number of patients in the overlap group. We 
assume this problem to be due to an extra layer of grouping. We tried to overcome this 
limitation through our alternative analyses, which showed significantly lower results in the 
sarcopenic groups with or without the overlap population. Future studies needed to shed 
more light on this subtype of wasting. 
4.1 Conclusions 
Sarcopenia and cachexia in HF are shown to be associated with higher morbidity and 
mortality (Anker et al. 1997, von Haehling et al. 2020). This study aimed to compare the 
impact of sarcopenia, cachexia, and their potential overlap on exercise tolerance and QOL 
among HF patients.  
In our study cohort, the overlap group showed the most significant lower functional 
performance and QOL. The sarcopenic HF group also presented similarly lower results in 
most of the functional tests, including CPET, 6MWT distance, SPPB, muscle strength, and 
EQ-5D index score. This effect remained constant after joining the overlap group into either 
the cachectic-HF or sarcopenic-HF. The cachectic HF group demonstrated some weaker 
results in peakVO2 and quadriceps strength. However, lower QOL was observed only in 
groups with characteristics of sarcopenia.  
Weight loss, as used to define cachexia, cannot comprehensively represent the body 
composition among HF patients. Sarcopenic patients, especially at the beginning of the 
disease, due to fatty tissue infiltration and inflammatory changes, may not show any 
measurable weight loss. Besides, due to other factors, e.g., peripheral edema, diuretic therapy, 
and obesity paradox, a simple scale cannot be reliable for evaluating HF patients. Early 
assessment of body composition with a DXA scanner should be implemented in the 
management of HF patients.  
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Our analysis could be helpful, particularly for the devolvement of therapeutic pathways to 
improve exercise tolerance and QOL in chronic HF. Due to prognostic significance, both 
sarcopenia and cachexia should be targeted to develop future treatments. However, 
sarcopenia might be the priority in this regard.  Future clinical trials need to address the 




Muscle wasting is acknowledged as a co-morbidity of heart failure (HF) and is associated 
with poor prognosis (ESC 2016). Cardiac cachexia is known to cause reduced functional 
capacity, more frequent hospitalization, and decreased survival rate (ESC 2016). This study 
aimed to compare the impacts of sarcopenia, cachexia, and their overlap on exercise 
tolerance and quality of life (QOL) in chronic HF patients.  
We included retrospectively 207 outpatients with chronic HF into a cross-sectional study 
based on the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) 
database. Body composition was measured using dual-energy X-ray absorptiometry (DXA). 
Functional performance was assessed with peak oxygen uptake (peakVO2), 6-minute-walk-
test (6MWT), and short physical performance battery (SPPB) test. The handgrip and 
quadriceps strength were measured using isokinetic dynamometry. Quality of life (QOL) was 
evaluated using the EuroQol-5-Dimension (EQ-5D) questionnaire to calculate the EQ-5D 
index score.   
Sarcopenia was present in 21.3% of our HF patients. In this context, 14.5% fulfilled 
sarcopenia's definition without associated cachexia (sarcopenic HF group). 12.1% presented 
with cachexia without concomitant sarcopenia (cachectic HF group). Furthermore, 6.8% of 
patients demonstrated the characteristics of both cachexia and sarcopenia (overlap group).  
The lowest results for functional capacity, muscle strength, and QOL were observed in 
patients with sarcopenia. Both of the overlap and sarcopenic HF groups showed the lowest 
values for muscle strength, 6MWT distance, peakVO2, SPPB score, and EQ-5D index score 
vs. control group (all p < 0.05). The overlap group showed the weakest quadriceps strength 
vs. all other groups (p < 0.05). We found significantly lower results for peakVO2 and 
quadriceps strength among the cachectic HF group vs. the control group, but this effect was 
not constant in other functional tests. The cachectic HF could not demonstrate significantly 
lower QOL indices.  
Male HF patients with sarcopenia seem to have significantly lower functional performance 
and QOL. These effects remain constant with/or without associated cachexia. Our study 
highlights the importance of early screening for sarcopenia among HF patients. In this 
regard, BMI cannot be a reliable representative of patients' body composition. 
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